pegylated interferon alpha

URI: https://gptkb.org/entity/pegylated_interferon_alpha
GPTKB entity
Statements (47)
Predicate Object
gptkbp:instanceOf gptkb:drug
biologic therapy
gptkbp:approvedBy gptkb:FDA
gptkb:EMA
2001
gptkbp:ATCCode L03AB11
gptkbp:brand gptkb:PegIntron
gptkb:Pegasys
gptkbp:CASNumber 198153-51-4
gptkbp:combines direct-acting antivirals
ribavirin
gptkbp:contraindication autoimmune hepatitis
decompensated liver disease
severe psychiatric disorders
gptkbp:developedBy gptkb:Schering-Plough
gptkb:Roche
gptkbp:discoveredIn 1990s
gptkbp:eliminationHalfLife about 50-80 hours
gptkbp:form solution for injection
gptkbp:halfLife longer than conventional interferon alpha
gptkbp:hasComponent interferon alpha
gptkbp:hasModification gptkb:plastic
https://www.w3.org/2000/01/rdf-schema#label pegylated interferon alpha
gptkbp:KEGGID D08144
gptkbp:legalStatus prescription only
gptkbp:mechanismOfAction immunomodulation
antiviral activity
gptkbp:MedlinePlusID a605018
gptkbp:metabolism renal
hepatic
gptkbp:pregnancyCategory C
gptkbp:PubChem_CID gptkb:CHEMBL1201562
16129680
DB00008
gptkbp:replacedBy direct-acting antivirals
gptkbp:routeOfAdministration subcutaneous injection
gptkbp:sideEffect gptkb:depression
gptkb:anemia
neutropenia
thrombocytopenia
flu-like symptoms
gptkbp:UNII J4N7LZ7Z1E
gptkbp:usedFor gptkb:hepatitis_C
gptkb:hepatitis_B
gptkbp:WHOModelListOfEssentialMedicines yes
gptkbp:bfsParent gptkb:Hepatitis_D
gptkbp:bfsLayer 6